Kennedy's deep HHS cuts threaten HIV/AIDS response
When Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced plans to reduce his department's staff by 20 percent, several divisions within the Centers for Disease Control and Prevention (CDC) were effectively eliminated, with programs focused on HIV and AIDS hit especially hard.
The entire staff at the Office of Infectious Diseases & HIV Policy (OIDP) was eliminated and other divisions dedicated to HIV were severely cut down. Both the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (NCHHSTP) as well as the Global Health Center Division of Global HIV & TB lost about a fourth of their staff.
Within the CDC's division of HIV prevention, five branches were eliminated completely, including the research, surveillance and prevention communication branches.
Top staffers including Jonathan Mermin, director of the NCHHSTP, and Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases (NIAID), were both reassigned to the Indian Health Service.
The United States spends around $28 billion on its domestic response to the HIV epidemic, which amounts to roughly one percent of HHS's FY 2025 budget of $2.61 trillion.
'I don't know why HIV has been singled out,' Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, told The Hill.
One of the teams that was let go oversaw guidelines for HIV PrEP. Schmid worries their absence could impact the implementation of a new investigational PrEP medication that, if approved, would only need to be administered twice a year.
Along with getting rid of entire branches crucial to the HIV response, Schmid noted hundreds of research grants have been halted.
Many of these grants were likely stopped due to the administration's edict to get rid of diversity, equity and inclusion (DEI) within the federal agencies. Some of the cut funding went towards HIV research focusing on trans, Black and Latino individuals, groups who are disproportionately impacted by the epidemic.
'I don't understand what 'No DEI' means. Because everything that we do is based on disparities — you know, whether you're Black, you're gay, you're trans — and also it could be geographic in certain areas. I mean, that's how you address an infectious disease. You go where the epidemic is,' said Schmid. 'If you ignore them, it's just going to get worse.'
Prior to becoming HHS secretary, Kennedy publicly questioned several aspects of the HIV epidemic, including whether the virus causes AIDS. He has promoted the idea that AIDS could be caused by the recreational drug poppers, popular in the gay community.
Kennedy has previously claimed that former longtime NIAID Director Anthony Fauci sabotaged effective AIDS treatments also cast doubt on the efficacy of azidothymidine (AZT), the first ever drug approved by the Food and Drug Administration to treat HIV and AIDS
When left untreated, HIV can lead to AIDS, a fact acknowledged by both the CDC and the World Health Organization.
Outside of conspiracy theories, Schmid sees echoes in the current administration of how the HIV epidemic was treated in the past, when government officials moralized the behavior of affected people and words like 'gay' and 'condom' couldn't be uttered in meetings. Now, terms like 'trans' and 'DEI' are being censored.
The apparent kneecapping of the federal response to HIV marks a contrast to President Trump's first term, when he launched an initiative of ending the HIV epidemic by 2030.
'I think there's some new people, you know, and I don't think they're reflective of where the country is,' Schmid said of current Trump administration and its actions on the HIV epidemic. 'It doesn't seem like it's very Trumpian either.'
Changes to the HIV response will also affect efforts in combatting other sexually transmitted infections (STI).
'The HIV and STI response in the United States is inextricably linked,' said David C. Harvey, executive director of the National Coalition of STD Directors.
'What happens to one program impacts the other program. What impacts these two distinct issues also impacts our larger ability to deal with infectious diseases in the U.S.' Harvey said.
According to Harvey, the federal government provides the majority of STI funding for some state health departments, meaning a drastic reduction at the federal level would be 'devastating' for them, particularly for 'rural, low-income southern states.'
Two branches of the CDC's STI division were also eliminated in Kennedy's culling: the STD Laboratory Reference Branch and the Disease Intervention and Response Branch. The cutting of these branches, coupled with the elimination of the OIDP and the HIV branches, means losing 'many, many years of scientific and administrative expertise,' according to Harvey.
The rate of STIs in the U.S. has been on the rise over the past two decades, with a 90 percent increase since 2004. It's only in recent years that the rate of STI infections has seemed to level off. From 2022 to 2023 the number of STIs in the U.S. fell by 1.8 percent.
Experts said defunding and eliminating these divisions runs counter to Kennedy's stated plans to focus on chronic illness over infectious disease. HIV, while manageable with today's medical advancements, is still currently a lifelong condition and other STIs can cause chronic illnesses.
'HIV and STIs squarely fall within the framework of chronic disease,' said Harvey. 'And we can do much more in this country to have an effective response to both prevent these diseases from ever happening and then if they do, provide universal access to testing and treatment.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape
The U.S. Alzheimer's disease diagnostics market, valued at USD 3.53 billion in 2024, is projected to grow at a CAGR of 10.6% from 2025-2030. Growth is driven by rising Alzheimer's prevalence and advanced diagnostics like FDA-approved blood tests, improving early detection and care planning. U.S. Alzheimer's Disease Diagnostics Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030" report has been added to U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030 This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics. The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/b-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.53 Billion Forecasted Market Value (USD) by 2030 $6.43 Billion Compound Annual Growth Rate 10.6% Regions Covered United States Competitive Landscape GE HealthCare Siemens Healthineers AG Canon Medical Systems Corporation Cerveau Technologies, Inc. Neurovision Imaging, Inc. Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. Quanterix Corporation Alzheon Inc. NanoSomiX, Inc. DiamiR Biosciences Company Overview Financial Performance Diagnostic Technique Portfolio Recent Developments/ Strategic Initiatives U.S. Alzheimer's Disease Diagnostics Market Report SegmentationDiagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030) Biomarkers CSF Biomarkers Blood-Based Biomarkers Imaging Diagnostic Techniques Genetic Testing Cognitive Assessment Tests Type Outlook (Revenue, USD Million, 2018 - 2030) Triage Diagnosis Screening End Use Outlook (Revenue, USD Million, 2018 - 2030) Hospitals Diagnostic Laboratories Academic & Research Institutes For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Alzheimer's Disease Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Washington Post
24 minutes ago
- Washington Post
Those annoying pharmaceutical ads have real value
Since stepping into the helm at the Department of Health and Human Services, Robert F. Kennedy Jr. has done his best to challenge traditional medicine. He has loosened vaccine recommendations for children and pregnant women, peddled baseless claims about the causes of chronic diseases, and championed alternative therapies such as 'healing farms.'


Boston Globe
an hour ago
- Boston Globe
Can Trump defeat ‘woke AI?'
'Woke' is right-wing shorthand for a variety of liberal projects aimed at achieving racial and gender fairness, often using means that conservative voters reject, such as racial preferences in hiring and college admissions. The Trump administration believes that these values have been embedded in the large language models (LLMs) that power many popular AI products, such as ChatGPT, leading them to produce information outputs that are slanted with liberal biases. Advertisement There's considerable evidence that this is true. Multiple studies by scholars at US and foreign universities have found that when asked political questions, the leading AI systems often favor more liberal perspectives on issues like abortion, climate change, or immigration. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In addition, there are high-profile examples of AIs generating false information in an apparent effort to reflect racial and ethnic diversity. Last year, a Google AI image generator depicted Black people when asked for images of Vikings and showed Black men and Asian women as World War II German soldiers. Of course, there's also evidence that AI is sometimes biased against minorities, women, and gay people. But this isn't a high priority for the Trump administration. Advertisement Instead, it's mainly worried about AIs that are trained to promote diversity, equity, and inclusion, or DEI. Hence, its new executive order seeks to purge DEI from all artificial intelligence systems used by the federal government. 'President Trump is protecting Americans from biased AI outputs driven by ideologies like diversity, equity, and inclusion (DEI) at the cost of accuracy,' said a statement issued by the administration. But Samir Jain, vice president of policy at the Center for Democracy and Technology, a tech-oriented political advocacy group, said the effort gets off to a bad start by mandating a ban on AI systems trained in DEI principles. 'The order itself is inherently contradictory,' said Jain, because eliminating DEI content from the training data will simply create a different form of bias. For example, he said, suppose the federal Equal Employment Opportunity Commission, which enforces civil rights laws, relies on an AI chatbot for researching racial or gender discrimination cases. If the chatbot is purged of DEI-related content, it might miss relevant court cases or academic research. 'Then that tool is no longer as useful,' Jain said. Massachusetts Democratic Senator Ed Markey went further, arguing that the Trump AI plan is unconstitutional. In a letter, Markey urged the heads of leading AI companies to resist the proposal. 'Republicans are using state power to pressure private companies to adopt certain political viewpoints, in this case by pressuring the Big Tech companies to ensure that responses from AI chatbots meet some unspecified, vague definition of ideological neutrality,' Markey said. Andrew Hall, professor of political economy at Advertisement For instance, the order states that government workers using AI should be able to request ideologically-slanted information if they see fit. Thus, an AI would be barred from automatically flagging evidence of racism in government contracting. But a federal worker would still be free to ask the AI to seek out such evidence. Still, purging all political bias from AI chatbots is probably impossible. 'Any model inherently reflects the priority viewpoints of the model builders,' said Jain. 'There's a real question whether there's anything you could call objective AI.' Hall agrees that political biases can never be completely purged from AI chatbots. But he notes that not all biases are bad. A chatbot ought to be biased against Nazi ideology, or lynchings, for example. The big challenge comes when dealing with less extreme controversies, where people of good will harbor major disagreements. How can an AI be trained to present a balanced point of view? Hall offers a possible solution. In a recent research paper, he concludes that people are good at spotting left-wing bias in AI-generated information, regardless of their own political views. 'Americans view the bulk of LLM output on hot-button political issues to be left-slanted,' said Hall. 'Even Democrats say this, on net.' His research also found that when people perceive an AI's output as unbiased, they are more inclined to trust it. Hall says that this discovery opens the door to 'a thoughtful approach that puts the American public in charge.' The leading AI bots could have their output regularly reviewed by panels of ordinary people, who'd grade the content for biases. Bot makers could tweak their output accordingly. Advertisement Whatever method might be used by AI vendors to comply with the executive order could be equally applied to commercial and consumer versions of their products. That could mean that in a few years all of us will be using AI systems that don't lean quite so far to the left. Hiawatha Bray can be reached at